

Global COVID-19 Clinical Platform WITH PREGNANCY MODULE – <u>CRF-P</u>


INTRODUCTION

In response to the COVID-19 pandemic, the World Health Organization (WHO) has launched a global COVID-19 anonymized clinical data platform (the "COVID-19 Data Platform") to enable State Parties to the International Health Regulations (IHR) (2005) to share with WHO anonymized clinical data related to patients with suspected or confirmed infections with SARS-CoV-2 (collectively "anonymized COVID-19 data"). The anonymized COVID-19 data received by WHO will remain the property of the contributing Entity and will be used by WHO for purposes of verification, assessment and assistance pursuant to the IHR (2005), including to inform the public health and clinical operation response in connection with the COVID-19 outbreak. To help achieve these objectives, WHO has established an independent Clinical Advisory Group to advise WHO on global reporting and analysis of the anonymized clinical COVID-19 data. State Parties and other entities are invited to contact WHO to obtain more information about how to contribute anonymized COVID-19 data, State Parties and other entities are respectfully requested to take all necessary measures to protect their respective log-in credentials and passwords to the COVID-19 Data Platform.

The anonymized COVID-19 data will be stored in the WHO COVID-19 Data Platform, which is a secured, access-limited, password protected electronic platform. WHO will (i) protect the confidentiality and prevent the unauthorized disclosure of the anonymized COVID-19 data; (ii) implement and maintain appropriate technical and organizational security measures to protect the security of the anonymized COVID-19 data and the COVID-19 Data Platform. In accordance with Article 11(4) of the IHR (2005), WHO will not make the anonymized COVID-19 data generally available to other State Parties or entities until such time as any of the conditions set forth in paragraph 2 of Article 11 are first met, and following consultation with affected countries/entities. Pursuant to that same Article 11, WHO will not make the anonymized COVID-19 data available to the public, unless and until the anonymized COVID-19 epidemic has already been made available to State Parties, and provided that other information about the COVID-19 epidemic has already become publicly available and there is a need for the dissemination of authoritative and independent information. To contribute data to the WHO COVID-19 Data Platform or to receive more information, please contact: COVID ClinPlatform@who.int

DESIGN OF THIS PREGNANCY MODULE CASE REPORT FORM (CRF-P)

The CRF is designed to collect data obtained through examination, interview and review of hospital notes. Data may be collected retrospectively if the patient data are obtained after the admission date. The data collection period is defined as the period from hospital admission to discharge, transfer, death, or continued hospitalization without possibility of continued data collection. This CRF-P should be completed for *pregnant women* or *recently pregnant women* who delivered within 21 days from onset of symptoms. If COVID symptoms started more than 21 days after the end of the pregnancy, please complete the Rapid Core CRF only.



The Pregnancy CRF has 3 sections:

Module 1: to be completed on the first day of admission to the health centre.

Module 2: to be completed daily during hospital stay for as many days as resources allow. Continue to follow-up patients who transfer between wards.

Module 3: to be completed at discharge or death.

GENERAL GUIDANCE

Participant identification numbers consist of a site code and a participant number. Please contact us at COVID_ClinPlatform@who.int, and our data management team will provide you with instructions for data entry and will assign you a 5-digit site code at that time.

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.



HIV

PREGNANCY MODUL	_E 1. Complete c	on hospita	aladmi	ission (within 24 hrs from hosp	oital adr	nissior	า)
Facility name:	acility name: Country:						
Date of enrolment: [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]							
1a. CLINICAL INCLUSIO	ON CRITERIA						
One or more	A history of self-re	eported fe	everish	ness or measured fever of ≥38°C	□Yes	□No	
of these	Cough □Yes □No						
during this	Dyspnoea (shortr	ness of bre	eath) C)R Tachypnoea*	□Yes	□No	
illness	Clinical suspicion	despite n	iot mee	ting criteria above	□Yes	□No	
* Respiratory rate ≥ 50 bre	aths/min for < 1 year	; ≥ 40 for 1	–4 year	rs; ≥ 30 for 5–12 years; ≥ 20 for ≥ 13 yea	rs		
1b. DEMOGRAPHICS						-	
	•			h [_D_][_D_]/[_M_][_M_]/[_Y_][_Y_]			
				rs OR [_][_] months OR [_]		ys	
				ratory worker? □Yes □No □Unk			
•			-	Gestational weeks assessment [
If currently pregnant or r	recently pregnant (d	elivery wit	thin 21	days of symptom onset), complete al	l section:	s of this	CRF
1c. DATE OF ONSET AN	DADMISSION VIT	ALSIGN	S (firsta	available data at presentation/admiss	ion)		
	1c. DATE OF ONSET AND ADMISSION VITAL SIGNS (first available data at presentation/admission) Symptom onset (date of first/earliest symptom) [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_]						
Admission date at this facility [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] Temperature [][].[]°C Heart rate [][][]beats/min Respiratory rate [][]breaths/min							
	BP [] [](systolic) [][][](diastolic)mmHg Severe dehydration □Yes □No □Unknown						11
Sternal capillary refill time > 2 seconds □Yes □No □Unknown							
	Oxygen saturation: [][]% on □Room air □Oxygen therapy □Unknown A V P U (circle one)						e)
Glasgow Coma Score		-		alnutrition			
Mid-upper arm circum	ference [][]	[]mm	He	eight: [] []cm Weig	jht: []		_]kg
1d. CO-MORBIDITIES (6	existing at admissic	n) (I Ink =	Inkno	nwn)			
Chronic cardiac disease (not hypertension)		<i>,</i> ,	∃Unk	Diabetes	□Yes	□No	□Unk
Hypertension	□Yes	□No □	∃Unk	Current smoking	□Yes	□No	□Unk
Chronic pulmonary dise	ase ⊡Yes	□No □	∃Unk	Tuberculosis (<i>active</i>)	□Yes	□No	□Unk
Asthma	□Yes	□No □	∃Unk	Tuberculosis (previous)	□Yes	□No	□Unk
Chronic kidney disease	□Yes	□No □	∃Unk	Asplenia	□Yes	□No	□Unk
Chronic liver disease	□Yes	□No □	∃Unk	Malignant neoplasm	□Yes	□No	□Unk
Chronic neurological dis	sorder □Yes	□No □	∃Unk	Other	□Yes	□No	□Unk
				If yes, specify:			

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

□Yes (on ART)

© World Health Organization 2020. Some rights reserved. This publication is available under the licence CC BY-SA 3.0 IGO. This publication is adapted from the COVID-19 Case Record Forms

□Yes (not on ART)

□No

□Unknown

ART regimen



1e. PRE-ADMISSION AND CH	IRONIC M	EDICA	TION We	ere any of the following taken with	in 14 da	iys of a	dmission
Angiotensin converting enz	yme inhib	itors (ACE inhi	bitors)? □Yes □No □Unkn	own		
Angiotensin II receptor bloc	kers (ARE	Bs)?		□Yes □No □Unkn	own		
Non-steroidal anti-inflamma	tory (NSA	ID)?		□Yes □No □Unkn	lown		
Antiviral? Chloroquine/hyd	roxychloro	quine	□ Azithr	omycin 🛛 Lopinavir/Ritonavir 🖾 Otl	her:		
1f. SIGNS AND SYMPTOMS F	Reported/a	assess	ed on th	e day of ADMISSION (Unk = Unkno	own)		
History of fever	□Yes	□No	□Unk	Lower chest indrawing	□Yes	□No	□Unk
Cough	□Yes	□No	□Unk	Headache	□Yes	□No	□Unk
with sputum production	□Yes	□No	□Unk	Altered consciousness/confusion	□Yes	□No	□Unk
with haemoptysis	□Yes		□Unk	Seizures	□Yes	□No	□Unk
Sore throat	□Yes	□No	□Unk	Abdominal pain	□Yes	□No	□Unk
Runny nose	□Yes	□No	□Unk	Vomiting/nausea	□Yes	□No	□Unk
Wheezing	□Yes	□No	□Unk	Diarrhoea	□Yes	□No	□Unk
Chest pain	□Yes	□No	□Unk	Conjunctivitis	□Yes	□No	□Unk
Muscle aches	□Yes	□No	□Unk	Skin rash	□Yes	□No	□Unk
Joint pain (arthralgia).	□Yes	□No	□Unk	Skin ulcers	□Yes	□No	□Unk
Fatigue/malaise	□Yes	□No	□Unk	Lymphadenopathy	□Yes	□No	□Unk
Loss of taste	□Yes	□No	□Unk	Inability to walk	□Yes	□No	□Unk
Loss of smell	□Yes	□No	□Unk	Bleeding (haemorrage)	□Yes	□No	□Unk
Shortness of breath	□Yes	□No	□Unk	If bleeding, specify site(s):			
Stroke: ischaemic stroke	□Yes	□No	□Unk				
Stroke: intracerebral haemorr			⊐No ⊡L	Ink			
Other If yes, specify:	□Yes	□No	□Unk				

1g. MEDICATION On the day of admission, did the patient receive any of the following:				
Oral/orogastric fluids? □Yes □No □Unknown Intravenous fluids? □Yes □No □Unknown				
Antiviral?				
If yes: Ribavirin Lopinavir/Ritonavir Neuraminidase inhibitor				
□Interferon alpha □Interferon beta □Other, specify:				
Corticosteroid?				
If yes, please provide agent and maximum daily dose:				
Antibiotic? □Yes □No □Unknown If yes, specify:				
Antifungal agent? □Yes □No □Unknown				
Antimalarial agent? □Yes □No □Unknown If yes, specify:				
Experimental agent? □Yes □No □Unknown If yes, specify:				
Non-steroidal anti-inflammatory (NSAID) □Yes □No □Unknown				
Angiotensin converting enzyme inhibitors (ACE inhibitors)				
Angiotensin II receptor blockers (ARBs) □Yes □No □ Unknown				
Systemic anticoagulation □Yes □No □Unknown				



1h. SUPPORTIVE CARE On the day of admission, did the patient receive any of the following:
ICU or high dependency unit admission?
Oxygen therapy? □Yes □No □Unknown If yes, complete all below
O₂ flow: □ 1–5 L/min □ 6–10 L/min □ 11–15 L/min □ > 15 L/min □ Unknown
Source of oxygen: Piped Cylinder Concentrator Unknown
Interface: Nasal prongs HF nasal cannula Mask Mask with reservoir CPAP/NIV mask Unknown
Non-invasive ventilation? (e.g. BIPAP/CPAP)
Invasive ventilation (any)? □Yes □No □Unknown If yes, what were the following values closest to 08:00: PEEP (cm H ₂ O); FiO ₂ (%); Plateau pressure (cm H ₂ O); PaCO ₂ ; PaO ₂ ;
Extracorporeal (ECMO) support? □Yes □No □Unknown
Prone position? □Yes □No □Unknown
Inotropes/vasopressors? □Yes □No □Unknown

i. LABORATORY RESULTS ON ADMISSION (*record units if different from those listed)									
Parameter	Value*	Units		Parameter	Value*	Units			
Haemoglobin		🗖 g/L	🗖 g/dL		Creatinine		🗖 mg/L	□ µmol/L	
WBC count		□ /mm ³	□ G/L (= x10 ⁹ /L)		Sodium		🗖 mEq/L	_ = mmol/L	
Haematocrit] %		Potassium		□ mEq/L = mmol/L		
Platelets		□ /mm³	□ G/L (= x10 ⁹ /L)		Procalcitonin		□ ng/mL	🛛 μg/L	
APTT/APTR		□ s	□ seconds CRP			🗖 mg/L			
PT (seconds)		□ seconds			LDH		□ IU/L		
INR					Creatine kinase		= 🗆 = IU/L	UKAT/L	
ALT/SGPT			IU/L		Troponin		□ ng/mL	□ µg/L	
AST/SGOT			IU/L		ESR		□ mm/hour		
Total bilirubin		□ mg/L	□ µmol/L		D-dimer		□ ng/mL	🛛 μg/L	
Urea (BUN)		□ g/L	🗖 mg/dL	□ mmol/L	Ferritin		□ ng/mL	□ µg/L	
Lactate		□ mg/dL	mmol/L		IL-6		Πp	og/mL	

1j. PREGNANCY STATUS UPON A	1j. PREGNANCY STATUS UPON ADMISSION				
Pregnant not in labour					
Pregnant in labour					
Postpartum [days]*	□ [days] Breastfeeding? □Yes □No				
Post-abortion/miscarriage					
Number of foetuses	□Singleton □Twin □Triplet □Other [number] □Unknown				
Best estimate of gestational age in completed weeks	[_W_][_W_]_weeks				

© World Health Organization 2020. Some rights reserved. This publication is available under the licence <u>CC BY-SA 3.0 IGO</u>. This publication is adapted from the COVID-19 Case Record Forms



1k. ABORTION OR MISCARRIAGE (prior to admission)					
Date of induced abortion or spontaneous abortion/miscarriage?	[D][D]/[M][M]/[2][0][Y][Y]				
Were symptoms of COVID-19 disease present at the time?	□Yes □No □Unknown				

1I. OBSTETRIC HISTORY

Number of previous pregnancies beyond 22 weeks gestation [number]Number of previous vaginal deliveries [number]Number of previous cesarean deliveries [number]

Im. Please tick any which apply to previous deliveries:				
Preterm birth (< 37 weeks' gestation)	□Yes □No □Unknown			
Congenital anomaly	□Yes □No □Unknown			
Stillborn	□Yes □No □Unknown			
Neonatal death (0–6 days)	□Yes [day:]□No □Unknown			
Weight < 2.5 kg	□Yes □No □Unknown			
Weight > 4.5 kg	□Yes □No □Unknown			

1n. ALCOHOL, DRUGS – RISK FACTORS DURING THIS PREGNANCY					
Alcohol consumption	□Yes □No □Unknown				
Illicit/recreational drug use	□Yes □No □Unknown				

Io. MEDICATIONS DURING THIS PREGNANCY (Prior to onset of current illness episode)					
	Acetaminophen/paracetamol	□Yes	□No	□Unknown	
Fever or pain treatment	NSAID/s	□Yes	□No	□Unknown	
	Other/s (specify): [1	
Anticonvulsants	□Yes □No □Unknown If yes, specify generic name: []			
Anti-nausea	□Yes □No □Unknown If yes, specify generic name: [J			
Prenatal vitamins and micronutrients	☐Yes ☐No ☐Unknown If yes, specify generic name: I				
Antivirals	□Yes □No □Unknown If yes, specify generic name: []			
Antibiotics	☐Yes ☐No ☐Unknown If yes, specify generic name: []			

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

© World Health Organization 2020. Some rights reserved. This publication is available under the licence <u>CC BY-SA 3.0 IGO</u>. This publication is adapted from the COVID-19 Case Record Forms

(CRF) published by ISARIC on behalf of Oxford University. WHO reference number: WHO/2019-nCoV/Pregnancy_CRF/2020.5



1p. ADMISSION SIGNS AND SYMPTOMS					
Vaginal watery discharge	□Yes	□No	□Unknown		
Vaginal bleeding	□Yes	□No	□Unknown		
Headaches	□Yes	□No	□Unknown		
Vision changes	□Yes	□No	□Unknown		
Right upper quadrant (abdominal) pain	□Yes	□No	□Unknown		
Decreased or no fetal movement	□Yes	□No	□Unknown		
Uterine contractions	□Yes	□No	□Unknown		

1q. FETAL HEART RATE (first available data at presentation/admission)				
Fetal heart rate	(FHR): [][] beats/min			

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020. © World Health Organization 2020. Some rights reserved. This publication is available under the licence <u>CC BY-SA 3.0 IGO</u>. This publication is adapted from the COVID-19 Case Record Forms (CRF) published by <u>ISARIC</u> on behalf of Oxford University. WHO reference number: WHO/2019-nCoV/Pregnancy_CRF/2020.5



PREGNANCY MODULE 2. Follow up (daily or as frequent as possible based on feasibility)

Date of follow up [D][D]/[M][M]/[2][0][Y][Y]

2a. VITAL SIGNS (record most abnormal value between 00:00 to 24:00)	
Temperature [][_].[]°C Heart rate [][][]beats per min Respiratory rate	te [][]breaths/min
BP [_] [_] (systolic) [_][_] (diastolic) mmHg Severe dehydration □Ye	es ⊟No ⊟Unknown
Sternal capillary refill time > 2 seconds	A V P U (circle one)
Oxygen saturation [][_]% on □Room air □Oxygen therapy □Unknown	GCS/15 [][]

2b. DAILY CLINICAL FEATURES (Unk = Unknown)							
Cough	⊡Yes	□No	□Unk	Confusion	□Yes	□No	□Unk
and sputum production	⊡Yes	□No	□Unk	Seizures	□Yes	□No	□Unk
Sore throat	□Yes	□No	□Unk	Vomiting/nausea	□Yes	□No	□Unk
Chest pain	□Yes	□No	□Unk	Diarrhoea	□Yes	□No	□Unk
Shortness of breath	⊡Yes	□No	□Unk	Conjunctivitis	□Yes	□No	□Unk
Loss of smell	⊡Yes	□No	□Unk	Myalgia	□Yes	□No	□Unk
Loss of taste	□Yes	□No	□Unk	Other, specify:			

2c. LABORATORY RESULTS (*record units if different from those listed)								
Parameter	Value*	Units			Parameter	Value*	Units	
Haemoglobin		g/L	g/dL		Creatinine		mg/L	µmol/L
WBC count		/mm ³	G/L (= x10 ⁹ /L)		Sodium		mEq/L	= mmol/L
Haematocrit			%		Potassium		mEq/L = mmol/L	
Platelets		/mm ³	G/L (= x10 ⁹ /L)		Procalcitonin		ng/mL	µg/L
APTT/APTR		se	conds		CRP		mg/L	
PT (seconds)		se	seconds		LDH		IU/L	
INR					Creatine kinase		IU/L	UKAT/L
ALT/SGPT		1	IU/L		Troponin		ng/mL	µg/L
AST/SGOT		I	IU/L		ESR		mm/hour	
Total bilirubin		mg/L	µmol/L		D-dimer		ng/mL	µg/L
Urea (BUN)		g/L	mg/dL	 mmol/L	Ferritin		ng/mL	µg/L
Lactate		mg/dL	mmol/L		IL-6		pg	ı/mL

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

© World Health Organization 2020. Some rights reserved. This publication is available under the licence <u>CC BY-SA 3.0 IGO</u>. This publication is adapted from the COVID-19 Case Record Forms



2d. MEDICATION At any time during this 24-hour hospital day, did the patient receive:						
Oral/orogastric fluids? Yes No Unknown Intravenous fluids? Yes No Unknown						
Antiviral? □Yes □No □Unknown If yes: □Ribavirin □Lopinavir/Ritonavir □Neuraminidase inhibitor						
□Interferon alpha □Interferon beta □Other, specify:						
Corticosteroid?						
If yes, please provide agent and maximum daily dose:						
Antibiotic?						
Antimalarial agent? UYes DNo DUnknown If yes, specify:						
Experimental agent? Ures No Unknown If yes, specify:						
Non-steroidal anti-inflammatory (NSAID)						
Angiotensin converting enzyme inhibitors (ACE inhibitors) □Yes □No □Unknown						
Angiotensin II receptor blockers (ARBs) □Yes □No □Unknown						
Systemic anticoagulation □Yes □No □Unknown						

2e. SUPPORTIVE CARE At any time during this 24-hour hospital day, did the patient receive:
ICU or high dependency unit admission? UYes No Unknown
Date of ICU/HDU admission [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □Unknown
ICU/HDU discharge date [D_][D_]/[M_][M_]/[2_][0_][Y_][Y_] DNot discharged yet DUnknown
Oxygen therapy? Yes No Unknown If yes, complete all below:
O₂ flow: □ 1–5 L/min □ 6–10 L/min □ 11–15 L/min □ > 15 L/min □Unknown
Source of oxygen: Piped Cylinder Concentrator Unknown
Interface: INasal prongs IHF nasal cannula IMask IMask with reservoir ICPAP/NIV mask IUnknown
Non-invasive ventilation? (e.g. BIPAP, CPAP)
Invasive ventilation (any)? □Yes □No □Unknown If yes, what were the following values closest to 08:00: PEEP (cm H ₂ O); FiO ₂ (%); Plateau pressure (cm H ₂ O); PaCO ₂ ; PaO ₂ ;
Extracorporeal (ECMO) support? □Yes □No □Unknown
Prone position?
Inotropes/vasopressors? □Yes □No □Unknown
Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown

2f. FETAL HEART RATE

Fetal heart rate (record most abnormal value	(FHR): [][] beats/min
between 00:00 to 24:00)	

2g. TREATMENT DURING HOSPITALIZATION At ANY time during hospitalization, did the patient receive/undergo:						
Tocolysis	□Yes □No □Unknown					
Induction of labour	□Yes □No □Unknown					
Blood transfusion	□Yes □No □Unknown					

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

PREGNANCY MODULE 3. Complete at discharge/death

3a. DIAGNOSTIC/PATHOGEN TESTING
Chest X-ray/CT performed? Yes No Unknown If yes: infiltrates present? Yes No Unknown
Was pathogen testing done during this illness episode? □Yes □No □Unknown If yes, complete all below:
Influenza virus: Positive Negative Not done If positive, type
Coronavirus: Positive Negative Not done If positive: MERS-CoV SARS-CoV-2 Other
Other respiratory pathogen: Positive Negative Not done If positive, specify
Viral haemorrhagic fever: Positive Negative Not done If positive, specify virus
Other pathogen of public health interest detected: If yes, specify:
Falciparum malaria: Positive Negative Not done

Non-falciparum malaria:
Positive
Negative
Not done HIV:
Positive
Negative
Not done

3b. COMPLICATIONS At any time during hospitalization did the patient experience:					
Shock	□Yes □No □Unknown	Bacteraemia	□Yes □No □Unknown		
Seizure	□Yes □No □Unknown	Bleeding	□Yes □No □Unknown		
Meningitis/encephalitis	□Yes □No □Unknown	Endocarditis	□Yes □No □Unknown		
Anaemia	□Yes □No □Unknown	Myocarditis/pericarditis	□Yes □No □Unknown		
Cardiac arrhythmia	□Yes □No □Unknown	Acute renal injury	□Yes □No □Unknown		
Cardiac arrest	□Yes □No □Unknown	Pancreatitis	□Yes □No □Unknown		
Pneumonia	□Yes □No □Unknown	Liver dysfunction	□Yes □No □Unknown		
Bronchiolitis	□Yes □No □Unknown	Cardiomyopathy	□Yes □No □Unknown		
Stroke: ischaemic stroke	⊡Yes ⊡No ⊡Unknown	Acute respiratory distress syndrome (ARDS)	□Yes □No □Unknown		
Stroke: intracerebral hemorrhage	□Yes □No □Unknown				
Other	□Yes □No □Unknown If Yes, specify:				

3c. MEDICATION W	hile hosp	italize	d or at discha	rge, were any of the following administered:
Oral/orogastric fluids?	□Yes	□No	□Unknown	
Intravenous fluids?	□Yes	□No	□Unknown	
Antiviral?	□Yes	□No	□Unknown	If yes: □Ribavirin □Lopinavir/ritonavir □Neuraminidase
				inhibitor □Interferon alpha □Interferon beta □Other,
				specify:
Corticosteroid?	□Yes	□No	□Unknown	If yes, route: □Oral □Intravenous □Inhaled
				If yes, specify agent and
				maximum daily dose:
Antibiotic?	□Yes	□No	□Unknown	If yes, specify:
Antifungal agent?	□Yes	□No	□Unknown	If yes, specify:
Antimalarial agent?	□Yes	□No	□Unknown	If yes, specify:
Experimental agent?	□Yes	□No	□Unknown	If yes, specify:
Non-steroidal anti-infla	mmatory	(NSA	ID) 🗆 Yes 🗆	No 🗆 Unknown
				If yes, specify:
Systematic anticoagula	tion □Ye	es ⊡l	No □Unknown	

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.



3d. SUPPORTIVE CARE At ANY time during hospitalization, did the patient receive/undergo:
ICU or high dependency unit admission? □Yes □No □Unknown If yes, total duration:days
Date of ICU admission [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □ N/A
Date of ICU discharge [_D_][_D_]/[_M_][_M_]/[_2_][_0_][_Y_][_Y_] □ In ICU at outcome □N/A
Oxygen therapy? DYes DNo DUnknown If yes, complete all: Total duration:days
O₂ flow: □ 1–5 L/min □ 6–10 L/min □ 11–15 L/min □ >15 L/min Source of oxygen: □Piped □Cylinder □Concentrator
Interface:
Non-invasive ventilation? (e.g. BIPAP, CPAP) □Yes □No □Unknown If yes, total duration:days
Invasive ventilation (any)? Image: Product of the second seco
Prone position? Yes DNo DUnknown If yes, total duration:days
Inotropes/vasopressors? □Yes □No □Unknown If yes, total duration:days Renal replacement therapy (RRT) or dialysis? □Yes □No □Unknown

3e. OUTCOME

Outcome: Discharged alive Despitalized Transfer to other facility Death Palliative discharge Unknown **Outcome date:** [D][D]/[M][M]/[2][0][Y][Y] DUnknown

If discharged alive, ability to self-care at discharge versus before illness:
Same as before illness:
Better:
Unknown

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.



Sections 3f-3i (to be completed if delivery happened within 21 days of symptom onset)

3f. DELIVERY, PREGN	ANCY AND MATERNAL OUTCOMES						
Delivery during admission	□Yes □No						
Delivery date							
Mode of delivery	□ Vaginal delivery □ Caesarean section						
Onset of labour Fetal presentation at delivery	 □ Spontaneous □ Induced □ Cesarean section before labour □ Unknown □ Cephalic □ Transverse □ Breech 						
Amniotic fluid at delivery	Clear Meconium stained Unkno	own					
Other maternal outcomes/pregnancy complications	Gestational diabetes Gestational hypertension Anaemia (Hb < 11 g/dL) Hyperemesis Intrauterine growth restriction Placental previa/accreta/percreta Bacterial infection prior to hospital visit Pre-eclampsia/eclampsia Placental abruption Preterm contractions Preterm labour Preterm rupture of membranes Early or midterm miscarriage	□Yes □Yes □Yes □Yes □Yes □Yes □Yes □Yes	□No □No □No □No □No □No □No □No □No □No	□Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown □Unknown			
	Haemorrhage If haemorrhage, which type: Embolic disease	🗆 Postpa	□No artum/intrap irtum haemo on-related □No				
	Anesthetic complication	□Yes	□No	□Unknown			

CRF-P: COVID19 CORE CASE RECORD FORM (RAPID) version 8 April 2020 WITH PREGNANCY MODULE_revised 13 July 2020.

3g. PREGNANCY STATUS AT DISCHARGE		
Pregnancy outcome	□Undelivered	
	□Spontaneous abortion	
	□Induced abortion	
	☐Missed abortion	
	□Macerated stillbirth	
	□Fresh stillbirth	
	□Livebirth	
	□Post-abortion/postpartum on admission	
Maternal death	□Yes □No	
If we have the former of the same dearth data is	□Abortive outcome	
If yes, what was the underlying cause of death?	□Hypertensive disorders in pregnancy, childbirth and the puerperium	
cause of death?	□Obstetric haemorrhage	
	□Pregnancy-related infection	
	□Other obstetric complication not included in above causes	
	□Unanticipated complications of management (e.g. anaesthesia-related complications)	
	□Indirect maternal death	
	□Obstetric death of unspecified cause	
	□Deaths from a coincidental cause (e.g. motor vehicle accident)	

3h. SAMPLE COLLECTION					
Any	□Amniotic fluid	_test description	_date of collection	result	
sampling	□Placenta	_test description	_date of collection_]	[result]	
conducted?	□Cord blood	_test description	_date of collection	result	
If so, please describe the	□Vaginal swab	_test description	_date of collection	result	
test and the results	□Faeces/rectal swab	[_test description]	_date of collection]	result]	
	□Pregnancy tissue in the case of fetal demise/induced abortion	[_test description]	[_date of collection]	result	
	□Breastmilk	_test description	_date of collection]	result	

3i. NEONATAL OUTCOMES		
Date of birth [DD/MM/YYYY]		
Time of birth [e.g. 14:21]		
Participant ID of the mother:		
	[Single digit Baby ID_]* *Complete one form per neonate	
COVID-19 lab test of foetus or	□Performed □Not performed □Unknown	
neonate	If yes: [_sample collected_] [_test description_][_date of collection] [result]	
Apgar score at 5 minutes	Score: [][]	
Gestational age	Weeks: [][] Days: []	
Birth weight	Grams: [][][]	
Respiratory distress syndrome	□Yes □No □Unknown	

Neonatal outcome	□Discharged healthy	
	Discharged with complications/sequelae	
	Details: []	
	□Clinical referral to specialist ward /other hospital	
	Details: []	
	Death Date of death: [D][D]/[M][M]/[Y]/[Y]]	
	□Unknown	

If neonate died, primary cause of	□Preterm/low birth weight
death	□Birth asphyxia
	□Infection
	□Birth trauma
	□Congenital/birth defects
	□Other
	□Unknown
Any congenital anomalies	□Neural tube defects
	□Microcephaly
	□Congenital malformations of ear
	□Congenital heart defects
	□Orofacial clefts
	□Congenital malformations of digestive system
	□Congenital malformations of genital organs
	□Abdominal wall defects
	□Chromosomal abnormalities
	□Reduction defects of upper and lower limbs
	□Talipes equinovarus/clubfoot